

THE CONTENT OF THIS ANNOUNCEMENT HAS BEEN PUBLISHED USING EQUITY STOCK CODE (STOCK CODE: 00853) ON 30 JULY 2021 AND IS NOW REPUBLISHED USING DEBT STOCK CODE (STOCK CODE: 40720) FOR THE DEBT HOLDERS INFORMATION.

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort Scientific Corporation**

**微創醫療科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

## **PROFIT WARNING**

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, “**the Group**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform holders of the Company’s shares and securities and potential investors that, based on unaudited consolidated financial statements currently available to the Board, the Group has recorded a loss attributable to equity shareholders of the Company for the six months ended 30 June 2021 of approximately between USD90 million and USD100 million, as compared with a loss of USD65.6 million for the same period of last year. This change was principally attributable to: (i) the impact of price reduction due to the nationwide centralized procurement policy on coronary stents; (ii) the significant year-on-year increase in expenditures on research and development; (iii) one-time transaction costs of convertible bond issuance.

At the same time, the Group achieved double digit year-on-year growth in sales revenue during the reporting period, which partially offset the aforementioned negative impact. Such growth was principally attributable to the significant increase in sales volume of coronary stents driven by the nationwide centralized procurement policy, rapid market penetration, contribution from new product launches, and the increase in elective surgeries from COVID-19 recovery.

As at the date of this announcement, the Company is still in the process of preparing and completing the interim results of the Group for the six months ended 30 June 2021 (the “**2021 Interim Results**”). The information contained in this announcement is a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or audit committee of the Company. Holders of the Company’s shares and securities and

potential investors are advised to read the Company's announcement for the 2021 Interim Results carefully, which is expected to be published before the end of August 2021. Holders of the Company's shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the PRC, 30 July 2021

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *For identification purpose only*